Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: An open-label randomized controlled pilot trial (SPAN-S)
Diabetes Therapy Sep 22, 2017
Awata T, et al. - The current study's goal was to examine the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitors were effective in preserving the β-cell function for long-term periods in patients with slowly progressive type 1 diabetes (SPIDDM) or latent autoimmune diabetes in adults (LADA). The authors recommended that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, could be more effective in preserving the β-cell function compared to insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
